Publications
Schram AM, Naqash AR, Haura EB, Riess JW, Ulahannan SV, Ou SI, Munster PN, Cheng ML, Gustafson WC, Bitman B, Friedman R, Penn R, Kar S, Seshadri V, Wang Z, Tao L, Yang YC, Singh M, Burris HA, Meyerowitz JG. The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 41056387
Chari A, van de Donk NWCJ, Dholaria B, Weisel KC, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodriguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi KK, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit D, Wäsch R. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025. PMID: 40983036
Smabers LP, Wensink GE, Verissimo CS, Doorn M, Yang T, Voskuilen T, Huismans MA, Valkenburg-van Iersel L, Cirkel GA, Gootjes EC, Verheul HMW, Jeurissen FJ, Bol GM, Nienhuis HH, Braat MNGJA, Cuppen E, Vries RGJ, van der Baan FH, Elias SG, Kranenburg O, Koopman M, Boj SF, Roodhart JML. Patient-derived organoids predict treatment response in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40982295
Aggarwal R, Rottey S, Bernard-Tessier A, Mellado B, Kosaka T, Stadler WM, Horvath L, Greil R, O'Neil B, Siddiqui BA, Bauernhofer T, Bilen MA, Eskens F, Sandhu S, Shaw C, Ju CH, Decato BE, Yu B, Aparicio A. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40689871
Chari A, Shenoy S, Kruyswijk S, Hilder B, O'Rourke L, van de Donk NWCJ. Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary. Future oncology (London, England). 2025. PMID: 40951933
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. European urology. 2025. PMID: 40954009
Barbuto S, Lee S, Stein J, Kuo SH, Quinn L, Spinner M, Stern Y. Home Training for Cerebellar Ataxias: A Randomized Clinical Trial. JAMA neurology. 2025. PMID: 40946705
Loh IK, Miller TE, Aggarwal R, Richmond TM. Improving Representation of Underserved Populations in Cardiovascular Research. Journal of the American Heart Association. 2025. PMID: 40932113
Courau T, Desai A, Wagner A, Combes AJ, Krummel MF. The coming era of nudge drugs for cancer. Cancer cell. 2025. PMID: 40939589
Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan E, Steri V, Porten SP, Koshkin VS, Friedlander TW, Feng FY, Lee JK, Wiita AP, Chu CE, Chou J. Modulating the PPAR? pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nature communications. 2025. PMID: 40931013
Kamgar M, Ko AH. Bridging the Gap: Molecular Profiling to Guide Treatment Selection in Metastatic Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40929645
Padilla G, Qi Y, Lee S, Spinner M, Coultry O, Barbuto S. Minimal Clinically Important Difference of the Scale for the Assessment and Rating of Ataxia. Movement disorders clinical practice. 2025. PMID: 40916838
Salami A, Adiele U, Coate G, Diolaiti M, Chen H, Lu J, Ashworth A, Patil M, Fleishman JS, Ramaraju A, Patel A, Patel H, Patel K, Murakami M, Ambudkar SV, Talele TT. Structure-activity relationship studies on 2-thienylidene substituted 3-oxo-2,3-dihydrobenzofuran-7-carboxamides as poly (ADP-ribose) polymerase inhibitors. Bioorganic chemistry. 2025. PMID: 40945025
Germani MM, Borelli B, Hashimoto T, Nakamura Y, Oldani S, Battaglin F, Bergamo F, Salvatore L, Stahler A, Antoniotti C, Shitara K, Venook A, Oki E, Muro K, Ugolini C, Soeda J, Lonardi S, Pietrantonio F, Lenz HJ, Modest DP, Yoshino T, Cremolini C. Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40906970
Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40902132
Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, Rubin B, Vashist R, Rodriguez-Monguio R, Cinar P, Anderson SA, Butte AJ. An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL. Blood advances. 2025. PMID: 40902085
Aggarwal R, Nicholls SJ, D'Alessio D, Bhatt DL. Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study. Progress in cardiovascular diseases. 2025. PMID: 40907677
Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies. JCO precision oncology. 2025. PMID: 40893049
Jang A, Tripathi N, Lanka SM, Kumar HLS, Jain P, Calaway A, Shoag JE, Vince R, Mendiratta P, Rao S, Garcia JA, Brown JR, Koshkin VS, Campbell MT, Singh P, Barata PC. Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? The oncologist. 2025. PMID: 40828887
Sirohi D, Cornelia Ding CK, Stohr BA, Balassanian R, Vohra P, Aggarwal R, Chan E, Greenland NY. The utility of next-generation sequencing in metastatic prostate cancer FNA biopsies. Cancer cytopathology. 2025. PMID: 40847760